Skip to content

Preoperative Assessment of Pathological Nipple Discharge With Delayed Ductal Imaging of Contrast-enhanced Mammography

Preoperative Assessment of Pathological Nipple Discharge With Delayed Ductal Imaging of Contrast-enhanced Spectral Mammography: an Exploratory Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06033573
Enrollment
60
Registered
2023-09-13
Start date
2023-08-01
Completion date
2024-08-01
Last updated
2023-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nipple Discharge

Keywords

pathologic nipple discharge, contrast-enhanced spectral mammography

Brief summary

The goal of the prospective, interventional, self-control, open, single-center clinical study: is to evaluate the value of the delayed ductal imaging of contrast enhanced Spectral Mammography acquired in 4-6 hours after the routine iopromide 370 mgI/ml-enhanced ductography for the clinical diagnosis of patients with suspected pathologic nipple discharge. The main questions aim to answer are: 1. Percentage of changes from baseline in imaging diagnosis caused by the results of delayed imaging. 2. The rate of reported examination-related adverse events occurred within 7 days of the delayed ductal imaging. 3. The average gland dose (AGD) of delayed ductal imaging. After enrollment, subjects underwent CESM again within 4-6 hours post completing previous routine ductography to obtain a late-phase ductal image, which contains a low-energy image and a subtracted image obtained from the post processing.

Detailed description

As an exploratory study, the study plans to conduct another imaging using contrast-enhanced spectral mammography (CESM) 4-6 hours after the routine iopromide 370 mgI/ml-enhanced ductography, so as to explore the optimization of the ductography technique and attempt to make a systematic description of the mammary duct structure in the Chinese population of patients with pathological nipple discharge, and thus to assess the clinical value of this delayed imaging protocol, including the effectiveness of the diagnostic dimension of the disease and the safety of the radiation dose and the degree of patient tolerance.

Interventions

After enrollment, subjects should undergo contrast-enhanced spectral mammography again within 4-6 hours post completing previous routine ductography to obtain a late-phase ductal image, which contains a low-energy image and a subtracted image obtained from the post processing

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Females aged 18-65 years old * Completed routine iopromide 370 mgI/ml enhanced ductography for initial clinical diagnosis of suspected pathological nipple discharge, under the recommendation of the clinician * Signed informed consent form for this study (signature and date) * Committed to complying with study procedures and cooperating with the conducting of the full study process * For women of childbearing age, should have taken contraceptive measures for at least one month prior to screening and must have a negative serum or urine pregnancy test, meanwhile committed to take contraceptive measures during the entire study and continue until a specified time after the end of the study

Exclusion criteria

* Pregnant or lactating women * Experienced any episode of adverse events or discomfort after ductography with iopromide 370 mgI/ml * Had any history of breast surgery, such as having undergone any invasive examination or surgical treatment due to the studied disease, including but not limited to breast duct micro-endoscopy, puncture biopsy, surgery, etc * The ductal discharge symptom is more likely caused by other diagnosed/highly suspected diseases rather than a breast lesion, such as pituitary adenomas * Other conditions are inappropriate for participation in this study judged by the investigator, such as the patient had difficulty to cooperate with ductography procedure, for example, loss of consciousness, communication impairment or nipple anomalies, and overly slender ducts

Design outcomes

Primary

MeasureTime frameDescription
Percentage of changes from baseline in imaging diagnosis caused by the results of delayed ductal imaging4-6 hours after the routine iopromide 370 mgI/ml-enhanced ductographyChanges include any of the following: 1. Changes in disease classification (based on The International Statistical Classification of Diseases, ICD-10) 2. Any changes in the number, location and\\or size (maximum and minimum diameters) of all lesions found 3. Changes in the severity/nature of the disease with reference to the Breast Imaging Reporting and Data System classification standard

Secondary

MeasureTime frameDescription
Diagnostic accuracy of delayed ductal imaging results for the nature of the lesion4-6 hours after the routine iopromide 370 mgI/ml-enhanced ductographyAccuracy = (Number of true positive + Number of true negative) /total number x 100% with using pathological findings as reference standard
Percentage of changes from baseline in imaging diagnosis caused by the results of delayed ductal imaging in patients with dense breasts.4-6 hours after the routine iopromide 370 mgI/ml-enhanced ductographyChanges include any of the following: 1. Changes in disease classification (based on The International Statistical Classification of Diseases, ICD-10) 2. Any changes in the number, location and\\or size (maximum and minimum diameters) of all lesions found 3. Changes in the severity/nature of the disease with reference to the Breast Imaging Reporting and Data System classification standard
Percentage of changes from baseline in imaging diagnosis caused by the results of delayed ductal imaging in patients with non-palpable breast mass/no abnormal findings on palpation4-6 hours after the routine iopromide 370 mgI/ml-enhanced ductographyChanges include any of the following: 1. Changes in disease classification (based on The International Statistical Classification of Diseases, ICD-10) 2. Any changes in the number, location and\\or size (maximum and minimum diameters) of all lesions found 3. Changes in the severity/nature of the disease with reference to the Breast Imaging Reporting and Data System classification standard
Kappa values for the evaluation of diagnostic imaging results of delayed ductal imaging by different radiologists.4-6 hours after the routine iopromide 370 mgI/ml-enhanced ductographyEvaluate the agreement on the diagnostic evaluation of delayed images by assessors using the Kappa test.
Scores for diagnostic confidence of radiologists before and after obtaining delayed ductal imaging result.4-6 hours after the routine iopromide 370 mgI/ml-enhanced ductographyon a 5-point rating scale (1-5)

Other

MeasureTime frameDescription
The rate of reported examination-related adverse events occurred within 7 days of delayed ductal imaging.7 days post delayed ductal imaging.Any discomfort and associated medical diagnoses post ductal imagine
The average gland dose of delayed ductal imaging.During imaging procedureTotal radiation of low-energy and subtracted images of delayed ductal imaging from the craniocaudal projection (CC) and the mediolateral projection (ML) of either mammary gland

Countries

China

Contacts

Primary ContactFan Yang, Dr.
fyang@vip.163.com008685726114
Backup ContactJuan Tao, Dr.
taojuan@hust.edu.cn008685726114

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026